Abstract：
This study aimed to identify the clinicopathological characteristics and prognostic value of CC chemokine receptor 7 (CCR7) expression in patients with head and neck squamous cell carcinoma (HNSSC).
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed in this meta-analysis. Up to the 2nd of July 2022 a search was conducted using five databases: PubMed, Embase, Scopus, ProQuest, and Web of Science. The methodological standards for the epidemiological research scale were used to assess the quality of the included articles, and Stata software was used to synthesize the meta-analysis.
We considered 13 of the 615 studies which included 1005 HNSCC patients. High expression of CCR7 increased the pooled odds ratio (OR) of advanced stage, tumor size, metastasis and recurrence by 2.82 [95% confidence interval (CI) 1.84 to 4.33], 2.48 (95% CI 1.68, to 3.67), 3.57, 95% CI 2.25 to 5.05) and 3.93 (95% CI 2.03 to 7.64), respectively. High CCR7 reduced overall patient survival [hazard ratio 2.62 (95% CI 1.59 to 4.32)].
This study showed that high expression of CCR7 in HNSCC tumors was significantly associated with worse clinicopathological and survival outcomes, suggesting that CCR7 and its pathway could be potential therapeutic strategies for HNSCC.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed in this meta-analysis. Up to the 2nd of July 2022 a search was conducted using five databases: PubMed, Embase, Scopus, ProQuest, and Web of Science. The methodological standards for the epidemiological research scale were used to assess the quality of the included articles, and Stata software was used to synthesize the meta-analysis.
We considered 13 of the 615 studies which included 1005 HNSCC patients. High expression of CCR7 increased the pooled odds ratio (OR) of advanced stage, tumor size, metastasis and recurrence by 2.82 [95% confidence interval (CI) 1.84 to 4.33], 2.48 (95% CI 1.68, to 3.67), 3.57, 95% CI 2.25 to 5.05) and 3.93 (95% CI 2.03 to 7.64), respectively. High CCR7 reduced overall patient survival [hazard ratio 2.62 (95% CI 1.59 to 4.32)].
This study showed that high expression of CCR7 in HNSCC tumors was significantly associated with worse clinicopathological and survival outcomes, suggesting that CCR7 and its pathway could be potential therapeutic strategies for HNSCC.
摘要：
UNASSIGNED：本研究旨在确定头颈部鳞状细胞癌（HNSSC）患者CC趋化因子受体7（CCR7）表达的临床病理特征和预后价值。
UNASSIGNED：本荟萃分析遵循系统评价和荟萃分析指南的首选报告项目。截至2022年7月2日，使用五个数据库进行了搜索：PubMed，Embase,Scopus,ProQuest,和WebofScience。采用流行病学研究量表的方法学标准对纳入文章的质量进行评估,使用Stata软件进行荟萃分析。
未经评估：我们考虑了615项研究中的13项，包括1005例HNSCC患者。CCR7的高表达增加了晚期的合并优势比（OR），肿瘤大小，转移和复发由2.82[95%置信区间(CI)1.84至4.33]，2.48（95%CI1.68，至3.67），3.57，95%CI2.25至5.05)和3.93(95%CI2.03至7.64)，分别。高CCR7降低患者总生存率[风险比2.62(95%CI1.59至4.32)]。
UNASSIGNED：这项研究表明，CCR7在HNSCC肿瘤中的高表达与更差的临床病理和生存结果显著相关，提示CCR7及其通路可能是HNSCC的潜在治疗策略。
UNASSIGNED：本荟萃分析遵循系统评价和荟萃分析指南的首选报告项目。截至2022年7月2日，使用五个数据库进行了搜索：PubMed，Embase,Scopus,ProQuest,和WebofScience。采用流行病学研究量表的方法学标准对纳入文章的质量进行评估,使用Stata软件进行荟萃分析。
未经评估：我们考虑了615项研究中的13项，包括1005例HNSCC患者。CCR7的高表达增加了晚期的合并优势比（OR），肿瘤大小，转移和复发由2.82[95%置信区间(CI)1.84至4.33]，2.48（95%CI1.68，至3.67），3.57，95%CI2.25至5.05)和3.93(95%CI2.03至7.64)，分别。高CCR7降低患者总生存率[风险比2.62(95%CI1.59至4.32)]。
UNASSIGNED：这项研究表明，CCR7在HNSCC肿瘤中的高表达与更差的临床病理和生存结果显著相关，提示CCR7及其通路可能是HNSCC的潜在治疗策略。
